Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment.

Sputum quantitative culture, acid-fast smear, days-to-positive by BACTEC, and Mycobacterium tuberculosis antigen 85 complex were monitored during therapy in 42 patients with pulmonary tuberculosis (TB). By BACTEC, 4 patients were persistently positive on days 90-180, and treatment ultimately failed in 2 of these. Antigen 85 expression increased in subjects in whom disease persisted (persisters) from days 0 to 14 when the difference between persisters and nonpersisters was statistically significant (P = .002). Only antigen 85 complex values at day 14 suggested TB persistence at or after day 90. All subjects with day 14 antigen 85 complex values < 60 pg/mL responded rapidly to treatment and were cured. Of those with values > 60 pg/mL, in 33% TB persisted at or after day 90 and treatment failed in 17%. Biologic factors expressed early in therapy, not related to compliance or resistance, may exert a substantial influence on outcome. The antigen 85 complex is critical in cell wall biosynthesis and is induced by isoniazid in vitro. Its induction may represent an adaptive transition to a persistent state during therapy.

[1]  A. Cunningham,et al.  Mycobacterial Stationary Phase Induced by Low Oxygen Tension: Cell Wall Thickening and Localization of the 16-Kilodalton α-Crystallin Homolog , 1998, Journal of bacteriology.

[2]  W. Rom,et al.  Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. , 1998, Chest.

[3]  G. Besra,et al.  Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. , 1997, Science.

[4]  K. Kaneda,et al.  In vivo induction of apoptosis in the thymus by administration of mycobacterial cord factor (trehalose 6,6'-dimycolate) , 1997, Infection and immunity.

[5]  N. Fujiwara.  [Distribution of antigenic glycolipids among Mycobacterium tuberculosis strains and their contribution to virulence]. , 1997, Kekkaku : [Tuberculosis].

[6]  C. Horn,et al.  Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins , 1996, Antimicrobial agents and chemotherapy.

[7]  P. Venkatesan,et al.  Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[8]  D. Crane,et al.  Stationary phase-associated protein expression in Mycobacterium tuberculosis: function of the mycobacterial alpha-crystallin homolog , 1996, Journal of bacteriology.

[9]  N. Hibler,et al.  Isoniazid induces expression of the antigen 85 complex in Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.

[10]  J C Sacchettini,et al.  Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. , 1995, Biochemistry.

[11]  T. Kocagöz,et al.  Quantitative culture of Mycobacterium tuberculosis from clinical sputum specimens and dilution endpoint of its detection by the Amplicor PCR assay , 1995, Journal of clinical microbiology.

[12]  J. Content,et al.  Nucleotide sequence of the 85B-protein gene of Mycobacterium bovis BCG and Mycobacterium tuberculosis. , 1994, DNA sequence : the journal of DNA sequencing and mapping.

[13]  D. Mitchison.  Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. , 1993, The American review of respiratory disease.

[14]  S. Ichiyama,et al.  Bacteriostatic and Bactericidal Activity of Antituberculosis Drugs against Mycobacterium tuberculosis, Mycobacterium avium‐Mycobacterium intracellulare Complex and Mycobacterium kansasii in Different Growth Phases , 1992, Microbiology and immunology.

[15]  C. Truffot-Pernot,et al.  Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice , 1992, Antimicrobial Agents and Chemotherapy.

[16]  A. Sanson,et al.  Purification and characterization of the 30,000 dalton native antigen of Mycobacterium tuberculosis and characterization of six monoclonal antibodies reactive with a major epitope of this antigen. , 1991, The Journal of laboratory and clinical medicine.

[17]  H. Wiker,et al.  A localization index for distinction between extracellular and intracellular antigens of Mycobacterium tuberculosis. , 1991, Journal of general microbiology.

[18]  J. Shin,et al.  Production of monoclonal antibodies to lipoarabinomannan-B and use in the detection of mycobacterial antigens in sputum. , 1990, Yonsei medical journal.

[19]  J. Ellner,et al.  Induction of interleukin 1 and tumor necrosis factor by mycobacterial proteins: the monocyte western blot. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Truffot-Pernot,et al.  Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. , 1989, The American review of respiratory disease.

[21]  S. Chaparas,et al.  Radioimmunoassay for detecting Mycobacterium tuberculosis antigen in cerebrospinal fluids of patients with tuberculous meningitis. , 1987, The Journal of infectious diseases.

[22]  D. Mitchison,et al.  Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[23]  D. A. Russo,et al.  Determination of mycobacterial antigens in sputum by enzyme immunoassay , 1986, Journal of clinical microbiology.

[24]  C. Self,et al.  Enzyme amplification--a general method applied to provide an immunoassisted assay for placental alkaline phosphatase. , 1985, Journal of immunological methods.

[25]  L. Praloran.  [Classification of pulmonary tuberculosis]. , 1953, Minerva medica.

[26]  A. S. Furman.  [Classification of pulmonary tuberculosis]. , 1962, Problemy tuberkuleza.